FULL DISCLOSURE: This is sponsored content for Cytophage Technologies.

In this interview, Dr. Steven Theriault, CEO of Cytophage Technologies Ltd. (TSXV:CYTO), presents phage therapy as a potentially revolutionary biotech solution. He illustrates its efficacy by citing a successful treatment of a severe infection in Ottawa, underscoring the increasing demand for alternative treatments to combat antibiotic resistance.

Dr. Theriault outlines Cytophage’s expansion strategy, focusing on South Asia with a new product launch in Bangladesh and partnerships with major poultry integrators. He also touches on the development of phage-based vaccines and the company’s focus on both animal and human applications.

Looking ahead, Dr. Theriault highlights Cytophage’s goals: revenue generation, advancement of human clinical trials, and formation of strategic partnerships. These reflect the company’s ambition to capitalize on the growing interest in phage therapy.

FULL DISCLOSURE: Cytophage Technologies is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of Cytophage Technologies. The author has been compensated to cover Cytophage Technologies on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.